Ignite Creation Date:
2024-05-06 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05335473
Status:
RECRUITING
Last Update Posted:
2023-04-06
First Post:
2022-04-13
Brief Title:
Iribrine Plus Tucidinostat in the Treatment of HRHER2 Advanced Breast Cancer After CDK46 Inhibitor Failure
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| HR Positive HER2 Negative Advanced Breast Cancer |
Keywords: